Tags

Type your tag names separated by a space and hit enter

Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
Pediatr Infect Dis J. 2010 Feb; 29(2):105-10.PI

Abstract

BACKGROUND

Infants less than 6 months of age are at high risk for influenza disease and influenza-related complications, but no vaccine is licensed for this population.

METHODS

A double-blind, randomized, placebo-controlled trial was conducted in 1375 healthy US infants 6 to 12 weeks of age. Subjects received 2 doses of trivalent inactivated influenza vaccine (TIV, Fluzone, sanofi pasteur; N = 915) or placebo (N = 460) 1 month apart in combination with indicated concomitant vaccines. Solicited adverse events were collected for 7 days following vaccination, and unsolicited adverse events for 28 days. Hemagglutination-inhibition antibodies to all 3 vaccine strains were measured following the second TIV/placebo dose.

RESULTS

No significant differences were seen between TIV and placebo groups for any safety outcome. Fever > or =38 degrees C within 3 days of vaccination was seen in 11.2% versus 11.7% of TIV versus placebo recipients. Serious adverse events within 28 days were reported in 1.9% of TIV and 1.5% of placebo recipients. Antibody responses to childhood vaccines were similar in both groups. Increased influenza-specific antibody responses in TIV recipients compared with placebo recipients were seen against all 3 strains in TIV recipients (P < 0.001), with better responses to influenza A strains noted. Reciprocal geometrical mean titer to H1N1, H3N2, and B were 33, 95, and 11 in TIV recipients versus 7, 9, and 5 for placebo recipients. Over 90% of TIV recipients had antibody > or =1:40 for at least 1 vaccine strain and 49.6% for 2 strains, versus 16.4% and 0.9% in placebo-recipients.

CONCLUSIONS

TIV administered to young infants beginning at 6 to 12 weeks of age is safe and immunogenic.

Authors+Show Affiliations

Department of Pediatrics, Division of Infectious Diseases, Children's Hospital Research Institute, University of Washington, Seattle, WA, USA. Janet.Englund@seattlechildrens.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19934787

Citation

Englund, Janet A., et al. "Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccine in Infants: a Randomized Double-blind Placebo-controlled Study." The Pediatric Infectious Disease Journal, vol. 29, no. 2, 2010, pp. 105-10.
Englund JA, Walter E, Black S, et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. Pediatr Infect Dis J. 2010;29(2):105-10.
Englund, J. A., Walter, E., Black, S., Blatter, M., Nyberg, J., Ruben, F. L., & Decker, M. D. (2010). Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. The Pediatric Infectious Disease Journal, 29(2), 105-10. https://doi.org/10.1097/INF.0b013e3181b84c34
Englund JA, et al. Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccine in Infants: a Randomized Double-blind Placebo-controlled Study. Pediatr Infect Dis J. 2010;29(2):105-10. PubMed PMID: 19934787.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. AU - Englund,Janet A, AU - Walter,Emmanuel, AU - Black,Steven, AU - Blatter,Mark, AU - Nyberg,Jack, AU - Ruben,Frederick L, AU - Decker,Michael D, AU - ,, PY - 2009/11/26/entrez PY - 2009/11/26/pubmed PY - 2010/3/31/medline SP - 105 EP - 10 JF - The Pediatric infectious disease journal JO - Pediatr. Infect. Dis. J. VL - 29 IS - 2 N2 - BACKGROUND: Infants less than 6 months of age are at high risk for influenza disease and influenza-related complications, but no vaccine is licensed for this population. METHODS: A double-blind, randomized, placebo-controlled trial was conducted in 1375 healthy US infants 6 to 12 weeks of age. Subjects received 2 doses of trivalent inactivated influenza vaccine (TIV, Fluzone, sanofi pasteur; N = 915) or placebo (N = 460) 1 month apart in combination with indicated concomitant vaccines. Solicited adverse events were collected for 7 days following vaccination, and unsolicited adverse events for 28 days. Hemagglutination-inhibition antibodies to all 3 vaccine strains were measured following the second TIV/placebo dose. RESULTS: No significant differences were seen between TIV and placebo groups for any safety outcome. Fever > or =38 degrees C within 3 days of vaccination was seen in 11.2% versus 11.7% of TIV versus placebo recipients. Serious adverse events within 28 days were reported in 1.9% of TIV and 1.5% of placebo recipients. Antibody responses to childhood vaccines were similar in both groups. Increased influenza-specific antibody responses in TIV recipients compared with placebo recipients were seen against all 3 strains in TIV recipients (P < 0.001), with better responses to influenza A strains noted. Reciprocal geometrical mean titer to H1N1, H3N2, and B were 33, 95, and 11 in TIV recipients versus 7, 9, and 5 for placebo recipients. Over 90% of TIV recipients had antibody > or =1:40 for at least 1 vaccine strain and 49.6% for 2 strains, versus 16.4% and 0.9% in placebo-recipients. CONCLUSIONS: TIV administered to young infants beginning at 6 to 12 weeks of age is safe and immunogenic. SN - 1532-0987 UR - https://www.unboundmedicine.com/medline/citation/19934787/Safety_and_immunogenicity_of_trivalent_inactivated_influenza_vaccine_in_infants:_a_randomized_double_blind_placebo_controlled_study_ L2 - http://dx.doi.org/10.1097/INF.0b013e3181b84c34 DB - PRIME DP - Unbound Medicine ER -